Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH1 | Q92800 | 13/20 | 1.00 |
| ▸ | EZH2 | Q15910 | 12/20 | 0.88 |
| ▸ | EED | O75530 | 3/20 | 0.88 |
| ▸ | RBBP4 | Q09028 | 3/20 | 0.88 |
| ▸ | SUZ12 | Q15022 | 3/20 | 0.88 |
| ▸ | RBBP7 | Q16576 | 3/20 | 0.88 |
| ▸ | AEBP2 | Q6ZN18 | 3/20 | 0.88 |
| ▸ | PRMT3 | O60678 | 2/20 | 0.88 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.88 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2591377 | 1.00 | EZH1 (1.00) | EZH1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL16767552 | 0.94 | EZH1 (0.92) | EZH1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL12180659 | 0.94 | EZH1 (1.00) | EZH1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL29351394 | 0.94 | EZH1 (0.92) | EZH1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL2594776 | 0.93 | EZH1 (0.87) | EZH1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL26183970 | 0.93 | EZH1 (0.87) | EZH1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL30459647 | 0.93 | EZH1 (0.87) | EZH1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL19366484 | 0.92 | EZH2 (0.89) | EZH1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL12180851 | 0.92 | EZH2 (0.88) | EZH1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL25272476 | 0.91 | EZH1 (0.84) | EZH1EZH2EEDRBBP4SUZ12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745138-A1 | THIO-GLUTARIMIDO ISOINDOLINONE DERIVATIVE, BIFUNCTIONAL PROTEIN DEGRADER CONTAINING SAME, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| EP-4678638-A1 | NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| CN-120202200-A | Oxo-isoindolinyl substituted tetrahydropyrimidinedione-based compounds and applications thereof | 标新生物医药科技(上海)有限公司 | 2025-06-24 | — | — | CN | disclosed |
| WO-2024245443-A1 | COMPOUND BASED ON OXOISOINDOLINYL SUBSTITUTED TETRAHYDRO-2-PYRIMIDONE, AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-12-05 | — | — | WO | disclosed |
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| WO-2024188209-A1 | NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-09-19 | — | — | WO | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |